Alexandra Gomez-Arteaga, MD, on Expanding Eligibility for Cell Transplant With Cell Therapy

Commentary
Video

The Assistant Professor of Medicine at Weill Cornell Medical College discussed the changing cell transplant landscape.

“There are different options of how we can do transplants. I always encourage our referring physicians to at least send the patients for a transplant consultation so that we can decide together if the transplant is the best strategy for the patients. We used to limit the referring...but now we have better ways and novel ways to do a transplant. Patients that used to be not eligible can now be eligible for this potential lifesaving and curative strategy.”

Orca-T allogeneic cell therapy treatment yielded benefits in non-relapse mortality, relapse free survival (RFS), and overall survival (OS) in patients with hematological malignancies compared with those treated with posttransplant cyclophosphamide (PTCy)-based myeloablative conditioning peripheral blood stem cell hematopoietic cell transplant. The findings, from a retrospective analysis, also show high RFS and OS at 2 years posttransplant, and that that patients treated with Orca-T had higher GvHD free survival(73% vs 54%).Orca-T is being evaluated in a randomized Phase 3 registrational trial (NCT05316701).

Data from the analysis were presented by Alexandra Gomez Arteaga, MD, Assistant Professor of Medicine and Anne Moore, MD, Clinical Scholar in Hematology-Oncology, Weill Cornell Medical College, at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024. CGTLive spoke with Arteaga to learn more about Orca-T and how the treatment landscape for hematological malignancies has shifted in the last several years. She discussed other important factors for treatment, including cell therapy for ethnically diverse patients that may not have many donor cell options.

REFERENCE
Gomez-Arteaga A, Oliai C, Patel SS, et al. A Retrospective Analysis Comparing Orca-T to Post-Transplant Cyclophosphamide Based Allogeneic Hematopoietic Cell Transplant in Patients with Matched Unrelated Donors Receiving Myeloablative Conditioning. Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas. Abstract #59
Related Videos
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Salvador Rico, MD, PhD, on Informing Clinical Trials With Natural History Studies in Dravet
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
© 2024 MJH Life Sciences

All rights reserved.